Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2019-01-01
2019-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intravenous Ketamine and Postoperative Pain Following Cesarean Section.
NCT03018301
Analgesia Effects of Intravenous Ketamine After Spinal Anesthesia for Non-elective Cesarean Section
NCT03450499
IV and Intrathecal Ketamine in Cesarean Section
NCT05679375
Effect of Intravenous Ketamine Infusion for Hemodynamic Stability in Patients Undergoing Caesarean Delivery.
NCT05865080
A Multicenter Study of the Efficacy and Safety of Esketamine for Analgesia During Cesarean Section
NCT04548973
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The patients were randomized in two groups:
* Group Ketamine: these patients recieved 0.25 mg/kg of Ketamin intravenously 5 minutes after the spinal anesthesia.
* Group Placebo: recieved 20 ml of normal saline solution intravenously 5 minutes after the spinal puncture.
The investigators recorded intra demographic, intraoperative and post operative data.
The main outcome was the analgesic score: the visual analog scale (VAS). dynamic VAS was also monitored at 24 hours post operatively.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ketamine Group
Patients recieving 0.25 mg/kg of ketamine 5 minutes after spinal anesthesia
0.25 mg/kg of Ketamine
patients will recieve 0.25mg/kg of ketamine intravenously 5 min after spinal anesthesia
Placebo Group
20ml of normal saline solution
20ml of normal saline solution intravenously 5 minutes after spinal anesthesia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
0.25 mg/kg of Ketamine
patients will recieve 0.25mg/kg of ketamine intravenously 5 min after spinal anesthesia
20ml of normal saline solution
20ml of normal saline solution intravenously 5 minutes after spinal anesthesia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Monofetal pregnancy
* scheduled for urgent or elective cesarean section under spinal anesthesia
Exclusion Criteria
* Post partum hemorrage
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mongi Slim Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mhamed Sami Mebazaa
Professor, head of department of anesthesia and critical care
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mongi Slim University Hospital
La Marsa, Tunis Governorate, Tunisia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ketamine cesarean
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.